Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Systemic scleroderma. Clinical and pathophysiologic aspects.

T Krieg1, M Meurer

  • 1Dermatology Clinic and Polyclinic, Ludwig-Maximilian University of München, FRG.

Journal of the American Academy of Dermatology
|March 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Proteasome-dependent protein quality control of the peroxisomal membrane protein Pxa1p.

Biochimica et biophysica acta. Biomembranes·2020
Same author

[37-year-old male with confluent papules and arcuate erythematosquamous plaques on the upper trunk and arms : Preparation for the specialist examination: part 22].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2018
Same author

[In memory of Prof. Dr. med. Dr. h.c. mult. Otto Braun-Falco].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2018
Same author

[Systemic treatment of vitiligo : Balance and current developments].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2017
Same author

[Pigmentation disorders].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2017
Same author

[Oculocutaneous and ocular albinism].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2017
Same journal

Real-world experience with extended deucravacitinib-biologic combination therapy in refractory psoriasis and psoriatic arthritis.

Journal of the American Academy of Dermatology·2026
Same journal

Acute-phase Disease and Super-responder Status Predict Reduced Relapse Risk After Ritlecitinib Withdrawal in Alopecia Areata: A Prospective Real-World Study.

Journal of the American Academy of Dermatology·2026
Same journal

Response to Kvist-Hansen et al. 'Baseline monocytes ≥925/μL appear to represent a rare outlier phenotype rather than a generalizable predictor of adalimumab response in hidradenitis suppurativa.'

Journal of the American Academy of Dermatology·2026
Same journal

Navigating Difficult Conversations: Contraceptive Communication with Transgender and Gender Diverse Patients Starting Isotretinoin.

Journal of the American Academy of Dermatology·2026
Same journal

Ultrasound-Guided Hyaluronidase Administration with Remote Expert Guidance for Vascular Adverse Events after Filler Treatment.

Journal of the American Academy of Dermatology·2026
Same journal

Adalimumab Biosimilars and Access Barriers in Dermatology.

Journal of the American Academy of Dermatology·2026
See all related articles

Systemic scleroderma is a connective tissue disease affecting multiple organs. Early diagnosis and vasoactive therapy are crucial, though fibrosis development remains a challenge.

Area of Science:

  • Rheumatology
  • Immunology
  • Pathology

Background:

  • Systemic scleroderma is a generalized connective tissue disease impacting skin, GI tract, lungs, heart, and kidneys.
  • Characterized by distinct forms like acroscleroderma and diffuse scleroderma, with varying progression rates.
  • Antinucleolar antibodies are common in patients, aiding classification and prognosis, but their pathogenic role is unclear.

Purpose of the Study:

  • To review the key aspects of systemic scleroderma, including its clinical manifestations, diagnostic markers, and therapeutic approaches.
  • To highlight the importance of early diagnosis and intervention in managing the disease.
  • To discuss current treatment strategies and limitations in managing scleroderma.

Main Methods:

  • Literature review of systemic scleroderma, focusing on pathogenesis, clinical presentation, and treatment.

Related Experiment Videos

  • Analysis of the role of antinucleolar antibodies in disease classification and prognosis.
  • Examination of therapeutic interventions, including vasoactive agents, anti-inflammatory drugs, and D-penicillamine.

    • Main Results:

    • Systemic scleroderma presents in various forms with significant organ involvement.
    • Antinucleolar antibodies are valuable for classification and prognosis.
    • Early diagnosis facilitates vasoactive therapy; anti-inflammatory and antifibrotic treatments have specific indications and limitations.

    Conclusions:

    • Early diagnosis and timely vasoactive therapy are essential for managing systemic scleroderma.
    • While certain treatments show benefit, effectively influencing fibrosis development remains a significant challenge.
    • Further research into the pathogenesis and treatment of systemic scleroderma is warranted.